Market Overview

Can Monsanto Stop The 'Billion Dollar Pest'?




Monsanto Co.

Monsanto (MON) will release FQ3'17 earnings before the market opens  on Wednesday, June 28th. Estimize and Wall Street are foreshadowing both EPS and Revenue to come in lower than the previous quarter. The Estimize community is more bullish in comparison to the Street for EPS, the Estimize consensus comes in at $1.88 vs. $1.74 for Wall Street. Switching to revenue we see that the Street is roughly in line with Estimize hovering around $4.1M. Last quarter we saw a big beat for Monsanto posting an EPS of $3.19, beating the street by 43 cents.

Monsanto owns 34 different types of seeds and farming chemicals used to protect various crops.They are also on the cusp of being the largest supplier of both seeds and crop chemicals if the acquisition by Bayer is approved. Furthermore, they were recently approved by the EPA to begin marketing their new insecticide, RNAi, with the intention of preventing western corn farmers from becoming victims of  the "billion dollar pest," otherwise known as the soybean cyst nematode. Based on these factors, Monsanto appears to be tightening their grasp on the agricultural market. Estimize's data highlights that Monsanto shows positive price movement 57% of the time in the 1 to 5 days post-earnings.

What are you expecting for MON? Get your estimate in here!

(Photo Credit: Josh Friedman)

The preceding article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.


Related Articles (MON)

View Comments and Join the Discussion!

Posted-In: BayerEarnings M&A News Trading Ideas